S-ClassAbout S-Class
E
ELVAI Stock Diagnostic Report
Elevance raises 2026 adjusted EPS guidance to at least $29 while targeting at least 12% growth in 2027
Elevance Health has raised its 2026 adjusted EPS guidance and set a growth target of more than 12% for 2027, which is positive.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$440.88Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support375.74
Near-Term Resistance440.67
02
FUNDAMENTALS
Financial & Fundamental Analysis
Elevance Health (ELV) has demonstrated clear fundamental improvement following its Q3 2026 earnings release, which increased the 2026 adjusted EPS by at least $29 and set a target for minimum 12% growth in 2027.
03
TECHNICAL VIEW
Technical Position & Response Criteria
With an RSI of 85.3 indicating an overbought condition, accompanied by an upward alignment of moving averages and a 1.26‑fold rise in trading volume, the market is entering a phase where it attempts to break through near the resistance line after burn‑off of supply.
Support375.74
Resistance440.67
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Elevance has raised its adjusted EPS guidance to a minimum of $29 for 2026, and aims for at least 12% growth in 2027.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-10-21)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.